Adherence to Subcutaneous Allergen Immunotherapy Is Suboptimal
A recent systematic review of real-world data that was published in the International Forum of Allergy and Rhinology shows that persistence and adherence to subcutaneous allergen immunotherapy is suboptimal, suggesting that many patients with allergic rhinitis who are treated with this therapy may not achieve long-term disease control.
@kanupriya A total of 17 real-world studies with 263,221 patients with allergic rhinitis met the inclusion criteria and were subsequently reviewed by the investigators. Studies included in this review enrolled children and adults ranging in age from 1 to 90 years. Ten studies were conducted in the United States. Other geographic locations included the Netherlands, Kuwait, Denmark, Turkey, Italy, and South Korea.